Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083566 | 0.97 | TAS1R3 (0.42) | TAS1R3TAS1R1ADORA1ADORA3ADORA2A | |
| SCHEMBL5083644 | 0.97 | ADORA1 (0.41) | TAS1R3TAS1R1ADORA1ADORA3ADORA2A | |
| SCHEMBL5083648 | 0.88 | DNPH1 (0.37) | ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL5086082 | 0.85 | NPC1 (0.36) | ABL1SRCADORA1ADORA2AADORA2B | |
| SCHEMBL5083000 | 0.83 | ADORA1 (0.41) | ABL1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5086004 | 0.82 | KDM4E (0.36) | SRCADORA2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5083021 | 0.79 | ADORA1 (0.47) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5082973 | 0.79 | ADORA1 (0.46) | ABL1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5083031 | 0.76 | FAP (0.37) | TAS1R3TAS1R1ABL1SRCADORA1 | |
| SCHEMBL5086442 | 0.76 | TAS1R3 (0.42) | TAS1R3TAS1R1ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | TAS1R3 3404/4885TAS1R1 4282/4885ABL1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.